PCV27: THE IMPACT OF ATHEROTHROMBOTIC EVENTS ON RESOURCE USE AND COST IN PATIENTS WITH PERIPHERAL ARTERIAL DISEASE  by Caro, J et al.
316 Abstracts
PCV26
RATES OF VENOUS THROMBOEMBOLISM AND
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IN AN INTEGRATED DELIVERY SYSTEM 
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Menzin J1
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OBJECTIVE: The objective of this study was to estimate
rates of venous thromboembolism (VTE) and inpatient
healthcare utilization following total hip replacement
(THR) or total knee replacement (TKR) surgery.
METHODS: Using a retrospective cohort approach and
inpatient data from a large Midwestern integrated health-
care organization, we evaluated all patients who under-
went a THR or TKR procedure between January 1, 1998
and September 30, 2000 and who received warfarin or
low-molecular-weight heparin (LMWH) prophylaxis
against deep vein thrombosis (DVT) during the initial
hospitalization. VTE rates (based on ICD-9-CM diag-
noses for pulmonary embolism or DVT) during the index
stay were estimated along with the associated incremen-
tal length of stay (LOS) and total charges. Time to VTE
occurrence within 90 days following index hospitaliza-
tion also was evaluated along with the associated LOS.
RESULTS: We identiﬁed 1411 patients who underwent
THR (N = 605) or TKR surgery (N = 806). For both pro-
cedures, warfarin was used 57% of the time versus 36%
for LMWH, while 7% of patients received both. The
mean LOS (±SD) for the initial hospitalization was 4.4 ±
2.0 days and mean charges were $22,150 ± $12,250. The
rate of VTE during the initial hospitalization was 1.1%
(15/1411) leading to an extra 3.7 ± 0.5 days (p < 0.01)
in hospital and $11,269 ± $3,168 in additional charges.
Following discharge, another 14 patients (1%) were read-
mitted for treatment of VTE with a mean LOS of 6.1 ±
7.8 days. Most of the readmissions for VTE (10 of 14)
occurred within 30 days. CONCLUSIONS: We found
that approximately 2% of patients receiving DVT pro-
phylaxis in this high-risk population were diagnosed with
thromboembolic events, which resulted in a signiﬁcant
health care burden and cost extending at least 90 days
beyond surgery. Whether this failure rate represents 
inadequate anti-coagulation or other risk factors requires
further study.
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OBJECTIVES: To estimate the resource use and costs
associated with atherothrombotic events following 
the diagnosis of peripheral arterial disease (PAD).
METHODS: We evaluated resource use and costs 
following a recorded diagnosis (identiﬁed using ICD-9
codes) of PAD using the healthcare records of residents
of Saskatchewan, Canada who were diagnosed between
1985–1995. Data on patient characteristics and medical
history were available from January 1980 and follow-up
was complete to December 2000. Rates of resource use
(hospitalizations, visits, procedures) were determined by
dividing the cumulative amount of use by the patient time
in a given period. Unit costs (2002 Canadian dollars)
were applied to the corresponding resource use to obtain
the mean costs. In this paper, the impact of athero-
thrombotic (myocardial infarction, angina, stroke, TIA)
hospitalizations is considered and compared to that in
patients with myocardial infarction and stroke.
RESULTS: Among 16,440 patients with PAD, 54.9%
were male, mean age was 67.3 years, 58% died during
follow-up, 85.8% were hospitalized at least once and one
third (37.1%) had at least one atherothrombotic-related
hospitalization, a hazard of 6.5/100 person-years. Among
those hospitalized, there were 2.1 atherothrombotic hos-
pitalizations on average. The hazard was highest imme-
diately following diagnosis (30.5/100PY) but dropped
rapidly to 25.3 in the second month, 16.8 by month 6
and 13.7 by the end of the ﬁrst year. This translated to a
monthly cost of $80.40 per patient in the ﬁrst month
(66.3% of total hospitalization cost), dropping to $45.70
at year end (77.1% of total). These atherothrombotic
event costs amounted to $28.3 million in years 2–5;
whereas, patients suffering a myocardial infarction or
stroke incurred $28.2 million and $31.0 million, respec-
tively. CONCLUSIONS: Hospitalizations for atherothro-
mbotic events account for a substantial portion of the
costs of managing patients with PAD.
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OBJECTIVES: To describe costs and utilization associ-
ated with common inpatient treatments for deep venous
thrombosis (DVT) and pulmonary embolism (PE).
METHODS: Data from medical records were collected
for DVT and PE admissions (identiﬁed using Diagnostic
Related Group [DRG] or All Patient Reﬁned DRG codes)
from 132 hospitals between January 1999 and December
2000. Admissions were classiﬁed by treatment, including
unfractionated heparin (UFH) and low-molecular-weight
heparin (LMWH) monotherapies, UFH with LMWH,
